[1] |
Bray F, Laversanne M, Sung H, et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2024, 74(3): 229-263.DOI: 10.3322/caac.21834.
|
[2] |
Forner A, Reig M, Bruix J.Hepatocellular carcinoma[J].Lancet, 2018,391(10127): 1301-1314.DOI: 10.1016/S0140-6736(18)30010-2.
|
[3] |
Villanueva A.Hepatocellular carcinoma[J].N Engl J Med, 2019,380(15): 1450-1462.DOI: 10.1056/NEJMra1713263.
|
[4] |
Demir T, Lee SS, Kaseb AO.Systemic therapy of liver cancer[J].Adv Cancer Res, 2021, 149: 257-294.DOI: 10.1016/bs.acr.2020.12.001.
|
[5] |
Anwanwan D, Singh SK, Singh S, et al.Challenges in liver cancer and possible treatment approaches[J].Biochim Biophys Acta Rev Cancer,2020, 1873(1): 188314.DOI: 10.1016/j.bbcan.2019.188314.
|
[6] |
Xu H, Zhang H, Li B, et al.Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and metaanalysis[J].BMC Cancer, 2024, 24(1): 1008.DOI: 10.1186/s12885-024-12772-y.
|
[7] |
Bai J, Huang M, Song B, et al.The current status and future prospects for conversion therapy in the treatment of hepatocellular carcinoma[J].Technol Cancer Res Treat, 2023, 22: 15330338231159718.DOI:10.1177/15330338231159718.
|
[8] |
Wang J, Zheng Z, Wu T, et al.Hepatic arterial infusion chemotherapy as a timing strategy for conversion surgery to treat hepatocellular carcinoma:a single-center real-world study[J].J Hepatocell Carcinoma, 2022, 9:999-1010.DOI: 10.2147/JHC.S379326.
|
[9] |
Cao Y, Tang H, Hu B, et al.Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis[J].HPB, 2023, 25(7): 775-787.DOI: 10.1016/j.hpb.2023.03.004.
|
[10] |
中国抗癌协会肝癌专业委员会转化治疗协作组.原发性肝癌转化及围手术期治疗中国专家共识(2024版)[J].中华消化外科杂志, 2024, 23(4): 492-513.DOI: 10.3760/cma.j.cn115610-20240228-00135.Alliance of Liver Cancer Conversion Therapy of Committee of Liver Cancer of China Anti-Cancer Association.Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition)[J].Chin J Dig Surg, 2024, 23(4): 492-513.DOI: 10.3760/cma.j.cn115610-20240228-00135.
|
[11] |
Luo L, He Y, Zhu G, et al.Hepatectomy after conversion therapy for initially unresectable HCC: what is the difference?[J].J Hepatocell Carcinoma, 2022, 9: 1353-1368.DOI: 10.2147/JHC.S388965.
|
[12] |
Li B, Qiu J, Zheng Y, et al.Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma[J].Ann Surg Open, 2021, 2(2): e057.DOI: 10.1097/AS9.0000000000000057.
|
[13] |
Yang Z, Hu Z, Fu Y, et al.Laparoscopic hepatectomy versus open hepatectomy after conversion therapy using transarterial chemoembolization or hepatic arterial infusion chemotherapy for patients with initially unresectable hepatocellular carcinoma[J].J Hepatocell Carcinoma, 2023, 10: 1157-1167.DOI: 10.2147/JHC.S417739.
|
[14] |
Zang M, Hu X, Yuan G, et al.Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma:a retrospective study[J].Int Immunopharmacol, 2023, 125(Pt A):111019.DOI: 10.1016/j.intimp.2023.111019.
|
[15] |
Finn RS, Qin S, Ikeda M, et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J].N Engl J Med, 2020,382(20): 1894-1905.DOI: 10.1056/NEJMoa1915745.
|
[16] |
Kudo M, Finn RS, Galle PR, et al.IMbrave150: efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in patients with Barcelona clinic liver cancer stage B unresectable hepatocellular carcinoma: an exploratory analysis of the phase Ⅲ study[J].Liver Cancer, 2022, 12(3): 238-250.DOI: 10.1159/000528272.
|
[17] |
Yi C, Chen L, Lin Z, et al.Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC[J].Hepatology, 2021, 74(5): 2544-2560.DOI: 10.1002/hep.31921.
|
[18] |
中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南 (2024年版) [J/OL].中华肝脏外科手术学电子杂志, 2024, 13(4):407-449.DOI: 10.3877/cma.j.issn.2095-3232.2024.04.001.Department of Medica Administration of National Health Commission of the People’s Republic of China.Clinical practice guideline for primary liver cancer(2024 edition)[J/OL].Chin J Hepat Surg(Electronic Edition), 2024, 13(4): 407-449.DOI: 10.3877/cma.j.issn.2095-3232.2024.04.001.
|
[19] |
Schaible A, Schemmer P, Hackert T, et al.Location of a biliary leak after liver resection determines success of endoscopic treatment[J].Surg Endosc, 2017, 31(4): 1814-1820.DOI: 10.1007/s00464-016-5178-1.
|
[20] |
刘飞, 李海, 巫强.无胆道重建肝切除术后胆漏危险因素的Meta分析[J].临床肝胆病杂志, 2022, 38(3): 594-600.DOI:10.3969/j.issn.1001-5256.2022.03.020.Liu F, Li H, Wu Q.Risk factors for bile leakage after hepatectomy without biliary reconstruction: a Meta-analysis[J].J Clin Hepatol,2022, 38(3): 594-600.DOI:10.3969/j.issn.1001-5256.2022.03.020.
|
[21] |
米星宇, 莫蕾, 苏文欣, 等.肝切除术后胆汁漏的影响因素分析[J].中国普通外科杂志, 2023, 32(2): 246-253.DOI:10.7659/j.issn.1005-6947.2023.02.010.Mi XY, Mo L, Su WX, et al.Analysis of influencing factors for bile leakage after hepatectomy[J].Chin J Gen Surg, 2023, 32(2): 246-253.DOI:10.7659/j.issn.1005-6947.2023.02.010.
|
[22] |
兰润虎, 王超, 史佳宇, 等.术前TACE治疗对肝细胞癌肝切除术后并发症影响的倾向性评分匹配研究[J].中华肝胆外科杂志, 2023,29(7): 510-515.DOI: 10.3760/cma.j.cn113884-20230310-00075.Lan RH, Wang C, Shi JY, et al.Effect of preoperative TACE on the complications after hepatectomy for hepatocellular carcinoma: a propensity score matching analysis[J].Chin J Hepatobiliary Surg,2023, 29(7): 510-515.DOI: 10.3760/cma.j.cn113884-20230310-00075.
|
[23] |
Xu H, Yu X, Hu J.The risk assessment and clinical research of bile duct injury after transcatheter arterial chemoembolization for hepatocellular carcinoma[J].Cancer Manag Res, 2021, 13: 5039-5052.DOI: 10.2147/CMAR.S303172.
|
[24] |
莫书天, 彭涛.肝癌切除术后胆汁漏并发症的预防及彭氏经胆囊测漏技术的应用[J].中国普外基础与临床杂志, 2023, 30(6): 641-645.DOI:10.7507/1007-9424.202303028.Mo ST, Peng T.Prevention of bile leakage after hepatectomy for hepatocellular carcinoma and application of Peng’s leakage test technology[J].Chin J Bases Clin Gen Surg, 2023, 30(6): 641-645.DOI:10.7507/1007-9424.202303028.
|
[25] |
Koch M, James Garden O, Padbury R, et al.Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery[J].Surgery,2011, 149(5): 680-688.DOI: 10.1016/j.surg.2010.12.002.
|
[26] |
Shehta A, Farouk A, Said R, et al.Bile leakage after hepatic resection for hepatocellular carcinoma: does it impact the short- and long-term outcomes?[J].J Gastrointest Surg, 2022, 26(10): 2070-2081.DOI:10.1007/s11605-022-05433-7.
|
[27] |
周斌, 张培建.胆管上皮细胞的生理及其与胆管疾病的相关性[J].中国普通外科杂志, 2007, 16(7): 681-683.DOI:10.7659/j.issn.1005-6947.2007.07.019.Zhou B, Zhang PJ.Physiology of bile duct epithelial cells and its correlation with bile duct diseases[J].Chin J Gen Surg, 2007, 16(7):681-683.DOI:10.7659/j.issn.1005-6947.2007.07.019.
|
[28] |
谭逢武, 许达峰, 郑进方.不可切除肝细胞癌转化治疗的研究进展[J].中华肝胆外科杂志, 2024, 30(5): 381-385.DOI: 10.3760/cma.j.cn113884-20240123-00028.Tan FW, Xu DF, Zheng JF.Advances in conversion therapy of unresectable hepatocellular carcinoma[J].Chin J Hepatobiliary Surg,2024, 30(5): 381-385.DOI: 10.3760/cma.j.cn113884-20240123-00028.
|
[29] |
Xu H, Liu F, Hao X, et al.Laparoscopically anatomical versus nonanatomical liver resection for large hepatocellular carcinoma[J].HPB,2020, 22(1): 136-143.DOI: 10.1016/j.hpb.2019.06.008.
|
[30] |
Liao K, Yang K, Cao L, et al.Laparoscopic anatomical versus nonanatomical hepatectomy in the treatment of hepatocellular carcinoma:a randomised controlled trial[J].Int J Surg, 2022, 102: 106652.DOI:10.1016/j.ijsu.2022.106652.
|